TransCelerate broadens access to shared COVID-19 trial data
As researchers embrace the benefit of openly shared data to improve trial design and accelerate development of COVID-19 therapeutics and vaccines, TransCelerate has expanded the data available on and access to its data-sharing platform.
On Wednesday, the non-profit collaboration TransCelerate BioPharma Inc. said it will include data from investigational arms of COVID-19 trials on its DataCelerate platform; only control data from clinical trials had been available previously.
Additionally, non-members will be able to access data related to the disease. TransCelerate said least two outside companies have expressed interest in sharing their clinical trial data.
DataCelerate is a data-sharing platform intended to improve study design by making de-identified, anonymized data -- both in vivo preclinical toxicology data and clinical data -- available to its 20 biopharma members (see “Data Distribution”).
“Increasing access and including the investigational product arm will improve future trial designs and facilitate collaboration and connection across the research community,” Janet Woodcock said in a statement. She is the therapeutics head of the Trump administration’s Operation Warp Speed (see “Woodcock Steps Away from CDER”).
In March, another non-profit data-sharing organization, Vivli, said it would waive all member and user fees to share and access data on its COVID-19 portal.
Wednesday’s news follows the launch of a data-sharing initiative by NIH. The COVID R&D consortium has also prioritized data sharing, specifically that of real-world data.
The National Center for Advancing Translational Sciences (NCATS) said Monday the National COVID Cohort Collaborative (NC3) will create a centralized data hub to address the lack of standardization in COVID-19 data collection and reporting. Through NC3, NCATS aims to accelerate the collection and analysis of clinical, laboratory and diagnostic data from hospitals and healthcare plans (see “NCATS Seeks to Create Hub for COVID-19 Data”).
Kathleen Gondek, who heads COVID R&D’s real-world data work, has told BioCentury that using RWD to understand the natural history of the disease can inform trial endpoints, inclusion criteria and therapeutic selection (see “The Pivotal Role of Real-World Data in a Pandemic”).